tetano
Editor, Senior Moderator
Eur J Med Res
. 2023 Feb 25;28(1):100.
doi: 10.1186/s40001-023-01072-z.
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
Karolina Dahms[SUP] 1 [/SUP], Agata Mikolajewska[SUP] 2 [/SUP], Kelly Ansems[SUP] 3 [/SUP], Maria-Inti Metzendorf[SUP] 4 [/SUP], Carina Benstoem[SUP] 3 [/SUP], Miriam Stegemann[SUP] 5 [/SUP]
Affiliations
Abstract
Background: At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the role of Anakinra in COVID-19 remains unanswered, especially in patients receiving different forms of respiratory support. Therefore, the objective of this systematic review is to assess the safety and effects of Anakinra compared to placebo or standard care alone on clinical outcomes in adult hospitalized patients with SARS-CoV-2 infection.
Methods: We searched the Cochrane COVID-19 Study Register (comprising MEDLINE, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, medRxiv, and the Cochrane Central Register of Controlled Trials (CCSR)) and the WHO COVID-19 Global literature on coronavirus disease database to identify completed and ongoing studies from inception of each database to December 13, 2021. Since then, we monitored new published studies weekly up to June 30, 2022 using the CCSR. We included RCTs comparing treatment with Anakinra to placebo or standard care alone in adult hospitalized patients with SARS-CoV-2 infection.
Results: We included five RCTs with 1,627 patients (n[SUB]Anakinra[/SUB] = 888, n[SUB]control[/SUB] = 739, mean age 59.63 years, 64% male). Random-effects meta-analysis was used to pool data. We found that Anakinra makes little or no difference to all-cause mortality at up to day 28 compared to placebo or standard care alone (RR 0.96, 95% CI 0.64-1.45; RD 9 fewer per 1000, 95% CI 84 fewer to 104 more; 4 studies, 1593 participants; I[SUP]2[/SUP] = 49%; low certainty of evidence).
Conclusions: Anakinra has no effect on adult hospitalized patients with SARS-CoV-2 infection regarding mortality, clinical improvement and worsening as well as on safety outcomes compared to placebo or standard care alone.
Trial registration: PROSPERO Registration Number: CRD42021257552.
Keywords: Anakinra; COVID-19; Hospitalization; Interleukin 1 receptor antagonist protein; Meta-analysis; SARS-CoV-2; Systematic review.
. 2023 Feb 25;28(1):100.
doi: 10.1186/s40001-023-01072-z.
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
Karolina Dahms[SUP] 1 [/SUP], Agata Mikolajewska[SUP] 2 [/SUP], Kelly Ansems[SUP] 3 [/SUP], Maria-Inti Metzendorf[SUP] 4 [/SUP], Carina Benstoem[SUP] 3 [/SUP], Miriam Stegemann[SUP] 5 [/SUP]
Affiliations
- PMID: 36841793
- PMCID: PMC9959952
- DOI: 10.1186/s40001-023-01072-z
Abstract
Background: At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the role of Anakinra in COVID-19 remains unanswered, especially in patients receiving different forms of respiratory support. Therefore, the objective of this systematic review is to assess the safety and effects of Anakinra compared to placebo or standard care alone on clinical outcomes in adult hospitalized patients with SARS-CoV-2 infection.
Methods: We searched the Cochrane COVID-19 Study Register (comprising MEDLINE, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, medRxiv, and the Cochrane Central Register of Controlled Trials (CCSR)) and the WHO COVID-19 Global literature on coronavirus disease database to identify completed and ongoing studies from inception of each database to December 13, 2021. Since then, we monitored new published studies weekly up to June 30, 2022 using the CCSR. We included RCTs comparing treatment with Anakinra to placebo or standard care alone in adult hospitalized patients with SARS-CoV-2 infection.
Results: We included five RCTs with 1,627 patients (n[SUB]Anakinra[/SUB] = 888, n[SUB]control[/SUB] = 739, mean age 59.63 years, 64% male). Random-effects meta-analysis was used to pool data. We found that Anakinra makes little or no difference to all-cause mortality at up to day 28 compared to placebo or standard care alone (RR 0.96, 95% CI 0.64-1.45; RD 9 fewer per 1000, 95% CI 84 fewer to 104 more; 4 studies, 1593 participants; I[SUP]2[/SUP] = 49%; low certainty of evidence).
Conclusions: Anakinra has no effect on adult hospitalized patients with SARS-CoV-2 infection regarding mortality, clinical improvement and worsening as well as on safety outcomes compared to placebo or standard care alone.
Trial registration: PROSPERO Registration Number: CRD42021257552.
Keywords: Anakinra; COVID-19; Hospitalization; Interleukin 1 receptor antagonist protein; Meta-analysis; SARS-CoV-2; Systematic review.